R&G PharmaStudies Co Ltd
SZSE:301333
Relative Value
The Relative Value of one R&G PharmaStudies Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 75.68 CNY, R&G PharmaStudies Co Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
R&G PharmaStudies Co Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
R
|
R&G PharmaStudies Co Ltd
SZSE:301333
|
7.3B CNY | 9.3 | 48.3 | 39.5 | 39.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD | 370.5 | 4 387.5 | 1 391.1 | 2 972.2 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
188.8B USD | 4.2 | 28.2 | 19.7 | 26.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
145.3B USD | 5.9 | 40.2 | 22.3 | 33.9 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW | 8.4 | 29 | 29.1 | 38.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.5B CHF | 5.6 | 38.8 | 28.4 | 28.4 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY | 6.6 | 19.4 | 19.7 | 19.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.1B USD | 5 | 26.9 | 19.7 | 23.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.9B USD | 1.7 | 20.5 | 11.5 | 17.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.6B USD | 6.9 | 31.8 | 23.4 | 26 | |
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.8B HKD | 7.3 | 34.8 | 24.4 | 24.4 |